Geron Corporation (NASDAQ:GERN) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, GERN is expected to report 3Q20 loss of $ 0.06 per share from revenue of $ 0.04 million.
For the full year, analysts anticipate top line of $ 0.20 million, while looking forward to loss of $ 0.25 per share bottom line.
Previous Quarter Performance
Geron Corporation came out with loss for the second quarter of $ 0.06 per share, from the revenue of $ 0.04 million. The quarterly revenues declined 60.00 percent compared with the same quarter last year. Wall street analysts are predicting, GERN to report 2Q20 loss of $ 0.06 per share from revenue of $ 0.06 million. The top line results fell short of analysts by $ 0.02 million or 33.33 percent.
Stock Performance
Shares of Geron Corporation traded up $ 0.07 or 3.91 percent on Wednesday, reaching $ 1.86 with volume of 2.32 million shares. Geron Corporation has traded high as $ 1.90 and has cracked $ 1.79 on the downward trend
The closing price of $ 1.86, representing a 138.67 % increase from the 52 week low of $ 0.75 and a 25.42 % decrease over the 52 week high of $ 2.40.
The company has a market capital of $ 577.47 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Geron Corporation will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.geron.com
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
